Pliant Therapeutics logo
Pliant Therapeutics
PLRX | NASDAQ
Chart Builder DCF Calculator
$0.69
-$0.01 (-1.00%)
At close: Nov 16, 2026, 4:00 PM ET
$0.68
-$0.01 (-1.00%)
After-hours: Nov 16, 2026, 4:06 PM ET

Pliant Therapeutics Company Profile

Company profile explained

Company Profile

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

Key Executives

Name Position
Bernard Coulie President, Chief Executive Officer & Director
Keith Lamont Cummings Chief Financial Officer
Minnie Kuo Chief Operating Officer
Bill DeGrado Scientific Founder
Christopher S. Keenan Vice President of Investor Relations & Corporate Communications
Daniel Park Senior Vice President of Development Operations
Dean Sheppard Scientific Founder & Member of Scientific Advisory Board
Delphine Imbert Chief Technical Officer
Hal Chapman Scientific Founder & Member of Scientific Advisory Board
Lily Cheung Chief Human Resources Officer
Monica Sandberg Vice President, Regulatory & Compliance
Rik Derynck Scientific Founder & Member of Scientific Advisory Board
Scott Peters Senior Vice President of Finance
Tim Machajewski Senior VP & Head of Research

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 3 Filing
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 8-K Current Report
Aug 11, 2026 10-Q Quarterly Report
Jul 13, 2026 3 Filing
Jul 13, 2026 4 Filing
Jul 13, 2026 3 Filing
Jul 13, 2026 4 Filing
View All SEC Filings ➞
Pliant Therapeutics
Pliant Therapeutics logo
Country United States
IPO Date Jun 3, 2020
Industry Biotechnology
Sector Healthcare
Employees 49
CEO Bernard Coulie

Contact Details

331 Oyster Point Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol PLRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001746473
CUSIP Number 729139105
ISIN Number US7291391057
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.